38 studies found for:    PRO-140 OR PRO-140[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
1 Recruiting Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection
Conditions: HIV;   Human Immunodeficiency Virus
Intervention: Drug: PRO 140 350mg weekly SQ injection.
2 Completed Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Condition: HIV Infections
Intervention: Drug: PRO 140
3 Completed
Has Results
PRO 140 by IV Administration in Adults With HIV-1 Infection
Condition: HIV Infections
Interventions: Drug: PRO 140;   Drug: Placebo
4 Recruiting PRO 140 for Human Immunodeficiency Virus Infection
Condition: HIV
Intervention: Biological: PRO 140
5 Completed
Has Results
Study of PRO 140 by Subcutaneous Administration in Adult Subjects With HIV -1 Infection
Conditions: HIV -1 Infection;   HIV Infections
Interventions: Drug: PRO 140 (humanized monoclonal antibody to CCR5);   Drug: Placebo Comparator
6 Not yet recruiting A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
Condition: HIV
Interventions: Drug: PRO 140;   Drug: Placebo
7 Completed A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
Condition: Allergic Asthma
Intervention: Drug: HAE1 (PRO98498)
8 Completed Study to Compare the Effect of Valsartan vs Atenolol on Pro-thrombotic State in Hypertensive Patients.
Condition: Hypertension
Intervention: Drug: valsartan/atenolol
9 Active, not recruiting Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: ustekinumab;   Drug: placebo
10 Active, not recruiting Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: ustekinumab;   Drug: placebo
11 Active, not recruiting Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects
Condition: Moderate to Severe Plaque Psoriasis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: placebo
12 Terminated Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
Condition: Severe Sepsis
Intervention: Other: Procalcitonin level
13 Unknown  Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury
Condition: Pediatric Traumatic Brain Injury
Interventions: Drug: Probenecid and N-acetyl cysteine;   Drug: Placebo
14 Terminated
Has Results
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel;   Drug: Carboplatin plus Paclitaxel
15 Active, not recruiting
Has Results
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Conditions: Hypertension, Pulmonary;   Ventricular Dysfunction, Left
Interventions: Drug: Riociguat (Adempas, BAY63-2521);   Drug: Placebo
16 Completed
Has Results
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Rosiglitazone;   Drug: Sulfonylurea;   Drug: Metformin
17 Completed Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901);   Drug: Insulin aspart;   Drug: Insulin Glulisine
18 Recruiting Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)
Condition: Hypertension
Intervention:
19 Recruiting Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Condition: Heart Failure
Interventions: Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo
20 Recruiting Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Condition: Heart Failure
Interventions: Drug: Vericiguat (BAY1021189) (1.25 mg);   Drug: Vericiguat (BAY1021189) (5 mg);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years